瑞替普酶用于急性心肌梗死治疗的有效性与安全性研究

目的比较瑞替普酶（Reteplase，r-PA）与尿激酶（UK）静脉溶栓治疗急性心肌梗死（AMI）的疗效和安全性。方法将本院收治的56例急性心肌梗死患者分为瑞替普酶组（Reteplase组）和尿激酶组（UK组），分别予以瑞替普酶和尿激酶溶栓治疗，对两组冠状动脉再通率、并发症及不良反应发生率、急性期病死率等方面的数据进行统计分析。结果瑞替普酶组的血管再通率明显高于尿激酶组，同时明显降低了其急性期病死率（P〈0．05）。两组并发症及不良反应发生率差异无统计学意义（P〉0．05）。结论瑞替普酶用于静脉溶栓治疗是安全、有效的。

Safety and efficacy of reteplase as thrombolytic therapy in treatment of acute myocardial infarction

Objective To compare the efficacy and safety of reteplase （r-PA） and urokinase （UK） for intravenous therapy in the treatment of acute myocardial infarction （AMI）. Methods Fifty-six patients with acute myocardial infarction admitted to hospital were randomly divided into Reteplase group and UK group, respectively given r-PA and UK thrombolytic therapy. The recanali-zation rate, incidence of complications. and adverse reactions, mortality in acute phase and other aspects of two groups were analyzed statistically. Results The recanalization rate of Reteplase group was significantly higher than that of the UK group, while obviously reduced the mortality in acute phase （P 〈 0.05）. The incidence of complications and adverse reactions were not different between two groups （P 〉 0.05）. Conclusion It is safe and efficient to use r-PA for intravenous thrombolytic therapy in the patients with AMI.